Brief: Seelos Therapeutics Amends SLS-002 Agreement

Seelos Therapeutics

11/04/2022 15:50

April 11 (Reuters) - Seelos Therapeutics Inc  SEEL.O :
    * SEELOS THERAPEUTICS ANNOUNCES AMENDMENT OF SLS-002
AGREEMENT TO
REPURCHASE THE REMAINING ROYALTIES PAYABLE TO PHOENIXUS AG FOR
SLS-002 (INTRANASAL RACEMIC KETAMINE PROGRAM), ALL FUTURE
SUCCESS AND COMMERCIAL BASED MILESTONES AND THE CHANGE OF
CONTROL FEE
    * SEELOS THERAPEUTICS INC - PARTIES HAVE AGREED TO TERMINATE
IN
FULL ALL CONTINGENT PAYMENT OBLIGATIONS TO VYERA AND ITS RELATED
ENTITIES UNDER PURCHASE AGREEMENT
    * SEELOS - FOR ADDITIONAL CASH AND STOCK PAYMENTS DUE BY
APRIL,
JULY 2022 & JAN. 2023, PARTIES TO TERMINATE CONTINGENT PAYMENT
OBLIGATIONS TO VYERA
    * SEELOS - AMENDMENT REMOVES ALL FUTURE ROYALTIES DUE TO
VYERA,
NEARLY $100 MILLION OF POTENTIAL FUTURE MILESTONES IN EVENT
PROGRAM WERE TO BE ACQUIRED

Source text for Eikon:  ID:nPnV27z9a 
Further company coverage:  SEEL.O 

 ((Reuters.Briefs@thomsonreuters.com;))